RU2332218C2 - Применение (2-имидазолин-2-иламино) хиноксалинов для лечения деменции и болезни паркинсона - Google Patents

Применение (2-имидазолин-2-иламино) хиноксалинов для лечения деменции и болезни паркинсона Download PDF

Info

Publication number
RU2332218C2
RU2332218C2 RU2005114505/14A RU2005114505A RU2332218C2 RU 2332218 C2 RU2332218 C2 RU 2332218C2 RU 2005114505/14 A RU2005114505/14 A RU 2005114505/14A RU 2005114505 A RU2005114505 A RU 2005114505A RU 2332218 C2 RU2332218 C2 RU 2332218C2
Authority
RU
Russia
Prior art keywords
neurons
alpha
apoptosis
death
receptors
Prior art date
Application number
RU2005114505/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2005114505A (ru
Inventor
Виль м Г. ТАТТОН (US)
Вильям Г. ТАТТОН
Ларри А. ВИЛЕР (US)
Ларри А. ВИЛЕР
Дэниэл В. ДЖИЛ (US)
Дэниэл В. ДЖИЛ
Джон Е. ДОНЕЛЛО (US)
Джон Е. ДОНЕЛЛО
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2005114505A publication Critical patent/RU2005114505A/ru
Application granted granted Critical
Publication of RU2332218C2 publication Critical patent/RU2332218C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
RU2005114505/14A 2002-10-08 2003-10-07 Применение (2-имидазолин-2-иламино) хиноксалинов для лечения деменции и болезни паркинсона RU2332218C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41703102P 2002-10-08 2002-10-08
US60/417031 2002-10-08

Publications (2)

Publication Number Publication Date
RU2005114505A RU2005114505A (ru) 2005-10-27
RU2332218C2 true RU2332218C2 (ru) 2008-08-27

Family

ID=32093952

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005114505/14A RU2332218C2 (ru) 2002-10-08 2003-10-07 Применение (2-имидазолин-2-иламино) хиноксалинов для лечения деменции и болезни паркинсона

Country Status (20)

Country Link
US (1) US20040116436A1 (enExample)
EP (1) EP1549314B1 (enExample)
JP (1) JP2006504741A (enExample)
KR (1) KR20050056235A (enExample)
CN (1) CN100370988C (enExample)
AT (1) ATE380551T1 (enExample)
AU (2) AU2003279874A1 (enExample)
BR (1) BR0314541A (enExample)
CA (1) CA2501348A1 (enExample)
DE (1) DE60318081T2 (enExample)
ES (1) ES2297233T3 (enExample)
HK (1) HK1080408B (enExample)
IL (1) IL167848A (enExample)
MX (1) MXPA05003665A (enExample)
NO (1) NO20051664L (enExample)
NZ (1) NZ539329A (enExample)
PL (1) PL376347A1 (enExample)
RU (1) RU2332218C2 (enExample)
WO (1) WO2004032934A1 (enExample)
ZA (1) ZA200502745B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2680526C1 (ru) * 2016-07-05 2019-02-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
DE102009043750A1 (de) * 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
WO2016089997A1 (en) * 2014-12-02 2016-06-09 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
CA3031528A1 (en) * 2016-08-01 2018-02-08 Cognoptix, Inc. System and method for detecting tau protein in ocular tissue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2176145C2 (ru) * 1995-05-26 2001-11-27 Пфайзер Инк. Синергическое лечение паркинсонизма
US20020111357A1 (en) * 1995-06-28 2002-08-15 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
DE69823868T2 (de) * 1997-12-04 2005-04-21 Allergan Inc Substituierte imidazole derivate mit agonistischähnlicher wirkung auf die alpha 2b oder 2b/2c adrenergischen rezeptoren
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
CA2402405C (en) * 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2176145C2 (ru) * 1995-05-26 2001-11-27 Пфайзер Инк. Синергическое лечение паркинсонизма
US20020111357A1 (en) * 1995-06-28 2002-08-15 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOPIN P. et al. Effects of acute and subchronic administration of dexefaroxan an alpha-2 adrenoceptor antagonist, on memory performance in young adult and aged rodents // J Pharmacol Exp Ther. 1999 Feb; 288(2): 798-804. 2002 Apr; 301(1): 187-96 реферат, он-лайн [Найдено в Интернет на (www.pubmed.com) 11.07.2007], PMID: 11907173 [PubMed - indexed for MEDLINE]. *
Болезни нервной системы, рук. под ред. Н.Н.Яхно и др. - М.: Медицина, 1995, т.2, с.144-148б, 152-158, 228-231. CHOPIN P. et al. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway // J Pharmacol Exp Ther. 1999 Feb; 288(2): 798-804. реферат, он-лайн. [Найдено в Интернет на (www.pubmed.com) 11.07.2007], PMID: 9918591 [PubMed - indexed for MEDLINE]. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2680526C1 (ru) * 2016-07-05 2019-02-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота

Also Published As

Publication number Publication date
US20040116436A1 (en) 2004-06-17
JP2006504741A (ja) 2006-02-09
MXPA05003665A (es) 2005-06-08
CN100370988C (zh) 2008-02-27
ZA200502745B (en) 2006-07-26
BR0314541A (pt) 2005-07-26
AU2010200730A1 (en) 2010-03-18
NZ539329A (en) 2007-11-30
CN1703222A (zh) 2005-11-30
HK1080408A1 (en) 2006-04-28
CA2501348A1 (en) 2004-04-22
RU2005114505A (ru) 2005-10-27
EP1549314B1 (en) 2007-12-12
WO2004032934A1 (en) 2004-04-22
NO20051664L (no) 2005-05-31
KR20050056235A (ko) 2005-06-14
IL167848A (en) 2010-11-30
DE60318081T2 (de) 2008-11-06
AU2003279874A1 (en) 2004-05-04
HK1080408B (en) 2008-08-08
EP1549314A1 (en) 2005-07-06
DE60318081D1 (de) 2008-01-24
PL376347A1 (en) 2005-12-27
ES2297233T3 (es) 2008-05-01
ATE380551T1 (de) 2007-12-15

Similar Documents

Publication Publication Date Title
Salloum et al. Naltrexone Utility in Depressed
AU2009238370B2 (en) Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration
US6379882B1 (en) Method for selecting compounds for treating ischemia-related cellular damage
AU2010200730A1 (en) Method of using (2-imidazolin-2-ylamino) quinoxalines in the treatment of dementia and parkinsons
US7101879B2 (en) Treatments for neurotoxicity in Alzheimer's Disease
JP2005531544A (ja) Ｅｇｆｒ経路の抑制による緑内障およびｎｏｓ−２発現により媒介される他の状態の治療方法
US10537567B2 (en) Kinase inhibitors for treatment of disease
US20190314379A1 (en) Methods of using cannabinoid cb2 receptor agonist compositions to suppress and prevent opioid tolerance and withdrawal in a subject
HK1081880B (en) Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
AU2011239265A1 (en) Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20121008